As shown in Figure 7C, the percentage of CD83+ pDCs was significantly higher in post-nRCT tumor tissues (36.7 ± 18.9% CD83+ pDCs) in comparison to pre-nRCT tumor specimens (3.2 ± 4.2% CD83+ pDCs), indicating that nRCT can profoundly enhance the proportion of mature pDCs in rectal cancer tissues. The gene discussed is CD83; the disease is neoplasm.